摘要
目的探讨卵巢癌组织及化疗期间腹水癌细胞（ＡＣＣ）与外周血淋巴细胞（ＰＢＬ）多药耐药基因（ＭＤＲ１）表达蛋白Ｐ１７０含量及其相关性。方法应用流式细胞免疫学方法，对４８例卵巢癌组织细胞、ＡＣＣ及ＰＢＬ的Ｐ１７０含量进行动态定量研究。结果术前２５％卵巢癌组织Ｐ１７０含量阳性；化疗期间ＰＢＬ及ＡＣＣＰ１７０含量均逐渐增高。结论卵巢癌细胞不仅可以原发表达Ｐ１７０，且可随化疗疗程的增加而耐药逐渐增强。
Objective To explore the correlation of MDR 1 (P glycoprotein, P 170 ) gene expression P 170 contents among neoplastic tissues, peripheral blood lymphocytes (PBL) and ascites cancerous cells (ACC) during chemotherapy. Methods Content of P 170 in cancer tissue, ACC and PBL was quantiated dynamicly by using flow cytometric immunologic method in 48 cases suffered from ovarian carcinoma.Results Cancer tissue showed positive P 170 in 25% of patients. During chemotherapy, P 170 content in PBL and ACC were statistically increased. A significant correlation of P 170 was found between PBL and ACC (0.01< P <0.05). Conclusion The results indicated that multidrug resistance was produced gradually during chemotherapy. Content of P 170 in PBL could probably be used as an indirect index of multidrug resistance for recurrent carcinoma or residual tumor.
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
1998年第5期287-289,共3页
Chinese Journal of Obstetrics and Gynecology
关键词
卵巢肿瘤
基因表达
多药耐药性
P糖蛋白
Ovarian neoplasms Gene expression Drug resistance, multiple Flow cytometry P glgeoprotein
